The landscape of medical treatments has experienced a significant development as the FDA has given approval for a new presentation of Celltrion's SteQeyma for pediatric psoriasis and psoriatic arthritis. SteQeyma, an ustekinumab biosimilar referencing Stelara, received authorization for a
In a significant development for cancer treatment, Merck & Co. has received the FDA's approval for Keytruda (pembrolizumab) to be used in a new treatment regimen targeting adults with certain head and neck squamous cell carcinoma (HNSCC). This marks a critical extension of Keytruda's application,
As temperatures cool and the common cold season descends, a significant health risk may be lurking unnoticed for many younger adults. Respiratory Syncytial Virus (RSV), once considered a pediatric and elderly threat, has raised concerns for adults aged 18 to 59 with underlying health conditions.
Ivan Kairatov is a renowned expert in the biopharma industry, particularly in the realms of technology and innovation. His expertise in research and development has helped shape advancements in targeted cancer therapies. We discuss the recent FDA approval of the tablet formulation of Brukinsa, a
Multiple myeloma remains a formidable challenge in oncology, known for its relentless cycle of relapse and treatment resistance. This blood cancer, which originates in plasma cells within the bone marrow, continues to affect patients profoundly, with around 6,240 individuals diagnosed annually in
Imagine facing the battle against a form of lung cancer so rare that it affects only about 2% of those diagnosed with non-small cell lung cancer (NSCLC). This is the reality for those with ROS1-positive NSCLC, a disease that could soon see transformative change with the approval of Nuvation Bio's
